IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF FLORIDA
CASE NO. 12-60704-CIV-SEITZ/SIMONTON (consolidated)

APOTEX, INC. and APOTEX CORP., Plaintiffs, v. MYLAN PHARMACEUTICALS INC., Defendant.	CASE NO. 12-60704-CIV-SEITZ/SIMONTON
APOTEX, INC. and APOTEX CORP., Plaintiffs, v. PFIZER INC., and GREENSTONE LLC, Defendants.	CASE NO. 12-60705-CIV-SEITZ/SIMONTON
APOTEX, INC. and APOTEX CORP., Plaintiffs, v. LUPIN PHARMACEUTICALS, INC. and LUPIN LTD., Defendants.	CASE NO. 12-60708-CIV-SEITZ/SIMONTON

NOTICE OF HEARING

PLEASE TAKE NOTICE that the undersigned will bring on for hearing before the Honorable Magistrate Judge Andrea M. Simonton the discovery matters described below at the following place and time:

PLACE: United States Courthouse
301 North Miami Avenue
8th Floor Courtroom
Miami, Florida 33128

DATE: Friday, March 1, 2013

TIME: 10:00 a.m.

Dispute 1

Plaintiffs Apotex, Inc. and Apotex Corp. (collectively "Apotex") and defendants Pfizer Inc. and Greenstone LLC (collectively "Pfizer") dispute whether Pfizer is entitled to all documents concerning comparisons of the inventions claimed in the patent-in-suit, U.S. Patent No. 6,531,486 ("Apotex's '486 patent"), or its foreign counterparts with (1) the disclosures of the prior art U.S. Patent No. 4,743,450 ("Pfizer's '450 patent") or (2) foreign counterparts of Pfizer's '450 patent.

- Pfizer's Request for Production No. 6 (as narrowed by Pfizer).

Dispute 2

The parties dispute whether Pfizer is entitled to all documents concerning the submission of or the decision not to submit prior art or other information to any foreign patent office during the prosecution of any foreign counterpart of Apotex's '486 patent.

- An aspect of Pfizer's Request for Production No. 10.

Dispute 3

The parties dispute whether Pfizer is entitled to all documents submitted to the Food and Drug Administration or any regulatory agency concerning the role and/or the state of magnesium in any quinapril products. (The claims of Apotex's '486 patent are directed to making "quinapril magnesium" by reacting quinapril (an ACE inhibitor) with alkaline magnesium compounds).

- Pfizer's Request for Production Nos. 22 and 23 (as narrowed by Pfizer).

Dispute 4

The parties dispute whether Pfizer is entitled to all testimony, declarations or affidavits given or submitted by inventor Bernard C. Sherman, the inventor named on the patent-in-suit in connection with any litigation or proceeding concerning (1) U.S. Patent No. 6,767,556, an analog of the '486 patent which, in language largely identical to the '486 patent claims reacting moexepril (another ACE inhibitor) with an alkaline magnesium compound to form "moexepril magnesium" or (2) any foreign counterpart of U.S. Patent No. 6,767,556.

- Pfizer's Request for Production No. 51.

I hereby certify that the parties have complied with the pre-filing conference requirements of Southern District of Florida Local Rule 7.1(a)(3).

Dated: February 12, 2013

/s/ Maria J. Beguiristain
Maria J. Beguiristain
Florida Bar No. 69851
WHITE & CASE LLP
Southeast Regional Financial Center
200 South Biscayne Boulevard, Suite 4900
Miami, FL 33131
Telephone: (305) 371-2700
Facsimile: (305) 358-5744
mbeguiristain@whitecase.com

Aaron Stiefel (*pro hac vice*)
Daniel P. DiNapoli (*pro hac vice*)
Soumitra Deka (*pro hac vice*)
KAYE SCHOLER LLP
425 Park Avenue
New York, NY 10022
Telephone (212) 836-8000
Facsimile: (212) 836-8689

Attorneys for Defendants Pfizer Inc. and Greenstone LLC.

CERTIFICATE OF SERVICE

I HEREBY CERTIFY that on the 12th day of February, 2013, I electronically filed the foregoing document with the Clerk of the Court using CM/ECF. I also certify that the foregoing document is being served this day on all counsel of record or pro se parties on the attached Service List via transmission of Notices of Electronic Filing generated by CM/ECF or in some other authorized manner for those counsel or parties who are not authorized to receive Notices of Electronic Filing.

By: /s/ Maria J. Beguiristain
Maria J. Beguiristain

SERVICE LIST

Counsel for Plaintiffs Apotex, Inc. and Apotex Corp.

Matthew S. Nelles
Fla. Bar. No. 009245
mnelles@broadandcassel.com
BROAD AND CASSEL LLP
1 Financial Plaza
100 S. E. 3rd Avenue
Suite 2700
Ft. Lauderdale, FL 33394
Telephone: (954) 764–7060
Facsimile: (954) 761–8135

Robert B. Breisblatt
robert.breisblatt@kattenlaw.com
Martin S. Masar III
martin.masar@kattenlaw.com
Dennis C. Lee
dennis.lee@kattenlaw.com
Suresh B. Pillai
suresh.pillai@kattenlaw.com
KATTEN MUCHIN ROSENMAN LLP
525 W. Monroe Street
Chicago IL 60607
Telephone: (312) 902-5200
Facsimile: (312) 902-1061

Counsel for Mylan Pharmaceuticals Inc.

Deepro R. Mukerjee
deepro.mukerjee@alston.com
Paki Banky
paki.banky@alston.com
ALSTON & BIRD LLP
90 Park Avenue, 12th floor
New York, New York 10016
Telephone: (212) 210-9400

Counsel for Lupin Pharmaceuticals, Inc.

Robert F. Green
rgreen@leydig.com
Brett A. Hesterberg
bhesterberg@leydig.com
Christopher T. Griffith
cgriffith@leydig.com
Peter H. Domer
pdomer@leydig.com
LEYDIG, VOIT & MAYER
Two Prudential Plaza, Suite 4900
Chicago, Illinois 60601-6731
Telephone: (312) 616-5600